Bank of Montreal’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-24,696
| Closed | -$138K | – | 4339 |
|
|
2024
Q2 | $138K | Sell |
24,696
-998
| -4% | -$4.35K | ﹤0.01% | 3146 |
|
|
2024
Q1 | $137K | Buy |
+25,694
| New | +$141K | ﹤0.01% | 3201 |
|
|
2023
Q3 | – | Sell |
-48,305
| Closed | -$966K | – | 4329 |
|
|
2023
Q2 | $966K | Buy |
+48,305
| New | +$1.15M | ﹤0.01% | 2203 |
|
|
2021
Q4 | – | Sell |
-239,933
| Closed | -$13.2M | – | 3950 |
|
|
2021
Q3 | $13.2M | Buy |
239,933
+94,749
| +65% | +$4.66M | 0.01% | 1139 |
|
|
2021
Q2 | $6.42M | Buy |
145,184
+142,129
| +4,652% | +$5.86M | ﹤0.01% | 1493 |
|
|
2021
Q1 | $125K | Buy |
3,055
+369
| +14% | +$17.1K | ﹤0.01% | 3305 |
|
|
2020
Q4 | $134K | Buy |
2,686
+1,780
| +196% | +$83.3K | ﹤0.01% | 3429 |
|
|
2020
Q3 | $40K | Sell |
906
-332
| -27% | -$14.5K | ﹤0.01% | 3535 |
|
|
2020
Q2 | $58K | Buy |
1,238
+1,189
| +2,427% | +$59.3K | ﹤0.01% | 3368 |
|
|
2020
Q1 | $2K | Sell |
49
-1,137
| -96% | -$57.1K | ﹤0.01% | 3899 |
|
|
2019
Q4 | $71K | Sell |
1,186
-113
| -9% | -$6.74K | ﹤0.01% | 3660 |
|
|
2019
Q3 | $73K | Buy |
1,299
+22
| +2% | +$1.24K | ﹤0.01% | 3452 |
|
|
2019
Q2 | $71K | Buy |
1,277
+1,019
| +395% | +$53.1K | ﹤0.01% | 3522 |
|
|
2019
Q1 | $13K | Buy |
258
+19
| +8% | +$845 | ﹤0.01% | 3802 |
|
|
2018
Q4 | $10K | Sell |
239
-141
| -37% | -$7.27K | ﹤0.01% | 3897 |
|
|
2018
Q3 | $26K | Sell |
380
-1
| -0.3% | -$76 | ﹤0.01% | 3625 |
|
|
2018
Q2 | $29K | Buy |
381
+74
| +24% | +$4.66K | ﹤0.01% | 3625 |
|
|
2018
Q1 | $16K | Hold |
307
| – | – | ﹤0.01% | 3635 |
|
|
2017
Q4 | $16K | Sell |
307
-7,931
| -96% | -$441K | ﹤0.01% | 3655 |
|
|
2017
Q3 | $491K | Buy |
8,238
+5,741
| +230% | +$347K | ﹤0.01% | 2281 |
|
|
2017
Q2 | $197K | Buy |
2,497
+1,908
| +324% | +$156K | ﹤0.01% | 2659 |
|
|
2017
Q1 | $49K | Sell |
589
-26,581
| -98% | -$1.98M | ﹤0.01% | 3090 |
|
|
2016
Q4 | $2.15M | Sell |
27,170
-93,960
| -78% | -$6.83M | ﹤0.01% | 1511 |
|
|
2016
Q3 | $8.48M | Sell |
121,130
-16,966
| -12% | -$940K | 0.01% | 891 |
|
|
2016
Q2 | $5.36M | Buy |
138,096
+6,828
| +5% | +$284K | 0.01% | 1075 |
|
|
2016
Q1 | $5.32M | Buy |
131,268
+11,366
| +9% | +$721K | 0.01% | 1015 |
|
|
2015
Q4 | $10.6M | Buy |
119,902
+46,020
| +62% | +$3.63M | 0.01% | 703 |
|
|
2015
Q3 | $5.47M | Buy |
+73,882
| New | +$6.15M | 0.01% | 940 |
|
|
2015
Q2 | – | Sell |
-1,908
| Closed | -$80K | – | 4144 |
|
|
2015
Q1 | $80K | Sell |
1,908
-2,585
| -58% | -$73.3K | ﹤0.01% | 2734 |
|
|
2014
Q4 | $69K | Buy |
4,493
+148
| +3% | +$1.89K | ﹤0.01% | 2934 |
|
|
2014
Q3 | $55K | Buy |
4,345
+4,265
| +5,331% | +$52.9K | ﹤0.01% | 3106 |
|
|
2014
Q2 | $1K | Buy |
+80
| New | +$912 | ﹤0.01% | 4592 |
|
Other funds holding EGRX
NCM
ACM
Bank of Montreal's EGRX Position: Q3 2024 in Review
Bank of Montreal sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2024, closing a stake of 24,696 shares — an estimated $138K sold.
Bank of Montreal first reported a position in EGRX in Q2 2014 and held it in 32 quarters. The position peaked at $13.2M in Q3 2021. 65 funds tracked by Wall St. Rank hold EGRX as of Q3 2024.
- Bank of Montreal reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2024 after selling out during the quarter.
- Bank of Montreal sold 24,696 Eagle Pharmaceuticals, Inc. shares in Q3 2024, an estimated $138K.
- Bank of Montreal first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2014 and held it in 32 quarters.
- Bank of Montreal's Eagle Pharmaceuticals, Inc. position peaked at $13.2M in Q3 2021.
- 65 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2024.
Based on Bank of Montreal's 13F filing for Q3 2024, filed 13 Nov 2024.